Healthcare entity
Every one of those 1 sits in a single category, market-trends. AstraZeneca is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 3.3 for the broader beat in this window.
Last mentioned: Mar 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. AstraZeneca is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 3.3 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 5.9. Lorundrostat appears in 1 tracked Healthcare story from March 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 38 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Lorundrostat. Shared-story counts are live from our verified record — not editorial picks.
Mineralys (MLYS) and Vuzix (VUZI) reported Q4 2025 results, highlighting divergent but critical paths in healthcare innovation: the clinical validation of next-generation hypertension therapies and the operational scaling of augmented reality in surgical settings. While Mineralys focuses on pivotal trial readouts for lorundrostat, Vuzix is navigating a transition toward OEM and high-margin medical software solutions.
Lorundrostat is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
